Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers. Issue 15 (October 2020)

• Record Type: Journal Article
• Authors: Farotti, Lucia; Paolini Paoletti, Federico; Simoni, Simone; Parnetti, Lucilla
• Is Part Of: Biomarker insights. Volume 2020:Issue 15(2020)
• Publication Date: 2020-10
• Subjects: Cerebrospinal fluid biomarkers -- Parkinson's disease -- alpha-synuclein -- Alzheimer's disease biomarkers -- lysosomal enzymes -- neurofilament light chain -- inflammation -- oxidative stress; Biochemical markers -- Periodicals; 572.43
• DOI: 10.1177/1177271920964077
• Languages: English
• ISSNs: 1177-2719

Abstract

Diagnosis of Parkinson's disease (PD) relies on clinical history and physical examination, but misdiagnosis is common in early stages. Identification of biomarkers for PD may allow for early and more precise diagnosis and provide information about prognosis. Developments in analytical chemistry allow for the detection of a large number of molecules in cerebrospinal fluid (CSF), which are known to be associated with the pathogenesis of PD. Given the pathophysiology of PD, CSF α-synuclein species have the strongest rationale for use, also providing encouraging preliminary results in terms of early diagnosis. In the field of classical Alzheimer's disease (AD) biomarkers, low CSF Aβ42 levels have shown a robust prognostic value in terms of development of cognitive impairment. Other CSF biomarkers including lysosomal enzymes, neurofilament light chain, markers of neuroinflammation and oxidative stress, although promising, have not proved to be reliable for diagnostic and prognostic purposes yet. Overall, the implementation of CSF biomarkers may give a substantial contribution to the optimal use of disease-modifying drugs.